The study is to evaluate the safety, feasibility, and preliminary efficacy of frozen FMT delivery via retention enema compared to lyophilized powder given in oral capsules as induction FMT in subjects with active UC. This study will also determine changes in microbiome (diversity and genera) and proportion of antibody-coated microbiota from baseline to after completion of FMT.

开始日期2023-12-15

申办/合作机构

University of Texas Health Science Center at Houston

NCT04371653 / Withdrawn临床2期IIT

A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Nonalcoholic Fatty Liver Disease (NAFLD)

Potential subjects with non-alcoholic fatty liver disease (NAFLD) will be identified by gastroenterologists (study investigators). Twelve eligible subjects with NAFLD will be randomly assigned to receive either active fecal microbiota transplantation in orally administered capsules or Placebo capsules and dosed twice weekly for 12 weeks. .

开始日期2023-12-01

申办/合作机构

University of Texas Health Science Center at Houston

NCT04373473 / Recruiting临床2期IIT

A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation (PRIM-DJ2727) Administered Orally in Combination With Standard of Care Therapy for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis

The purpose of the study is to evaluate the efficacy and safety of lyophilized PRIM-DJ2727 capsules given orally in subjects with ulcerative colitis at remission stage. This study will also include longitudinal analyses of recipient's gut microbiota taxonomy and metagenomics to determine potential associations with clinical outcomes in context of active FMT or placebo administration.

开始日期2020-09-14

申办/合作机构

University of Texas Health Science Center at Houston

100 项与 PRIM-DJ2727 相关的临床结果

登录后查看更多信息

100 项与 PRIM-DJ2727 相关的转化医学

登录后查看更多信息

100 项与 PRIM-DJ2727 相关的专利（医药）

登录后查看更多信息

100 项与 PRIM-DJ2727 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
溃疡性结肠炎	临床1期	美国	University of Texas Health Science Center at Houston	2023-03-27
代谢功能障碍相关的脂肪肝病	药物发现	-	University of Texas Health Science Center at Houston	2023-12-01
帕金森病	药物发现	美国	University of Texas Health Science Center at Houston	2019-05-15
HIV感染	药物发现	美国	University of Texas Health Science Center at Houston	2018-04-12
艰难梭菌感染	药物发现	美国	University of Texas Health Science Center at Houston	2017-12-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MDS2021	N/A	帕金森病	12	PRIM-DJ2727 capsules	鏇艱膚膚遞遞遞鏇襯齋(鹽鏇廠齋蓋築蓋窪範憲) = 夢憲願淵積憲遞鹽築鏇鏇選鏇積鹽顧鹽觸糧淵 (淵艱膚糧糧鬱繭衊觸壓 ) 更多	-	2021-09-17
NCT03298048 (CTgov)	临床2期	艰难梭菌感染	17	Low fecal microbiota dose (Low Fecal Microbiota Dose)	製繭壓遞艱製餘糧膚艱(醖遞衊遞糧鹽壓製淵窪) = 鏇襯窪網觸膚選遞製觸範積鹽窪範艱積窪鏇獵 (鹽夢艱淵鹹鑰壓製簾鹹, 鏇壓構膚鏇壓糧鏇獵醖 ~ 網襯鑰範遞構鏇齋範築) 更多	-	2020-03-06
NCT03298048 (CTgov)	临床2期	艰难梭菌感染	17	Mid fecal microbiota dose (Mid Fecal Microbiota Dose)	製繭壓遞艱製餘糧膚艱(醖遞衊遞糧鹽壓製淵窪) = 齋蓋憲鏇鏇壓範糧夢壓範積鹽窪範艱積窪鏇獵 (鹽夢艱淵鹹鑰壓製簾鹹, 簾繭繭窪衊淵壓糧簾遞 ~ 遞顧積繭憲廠鑰壓觸簾) 更多	-	2020-03-06